治疗局部性前列腺癌后的年龄70+/- 5年和癌症特异性结果:系统性审查
Haitham Shaheen1, Mia A Salans2, Osama Mohamad3
1Clinical Oncology, Suez Canal University Hospital, Ismailia, Egypt.
International journal of radiation oncology, biology, physics
|October 3, 2023
概括
高龄 (≥70岁) 是前列腺癌患者接受外部束辐射疗法 (EBRT) 治疗的有利预后因素,但对于那些接受激进前列腺切除术 (RP) 的人来说是不利的因素.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 老年医学 老年医学
背景情况:
- 现有研究对前列腺癌治疗中年龄较大的预后意义提出了相互矛盾的发现.
- 一些研究表明,老年有利于外部束辐射疗法 (EBRT),而另一些研究表明,它不利于激进前列腺切除术 (RP).
研究的目的:
- 根据治疗方式,调查年龄对前列腺癌结果的矛盾影响.
- 为了确定年龄是否与治疗类型 (RP与EBRT) 相互作用,以影响癌症特异性结果.
主要方法:
- 1999年1月至2023年1月期间发表的研究的系统综述,来源于PubMed.
- 包括 45 项研究 (30 RP, 15 EBRT) 评估年龄 (截止值 70 ± 5 年) 和癌症特异性结果.
- 评估了年龄和治疗类型之间的相互作用,对生物化学失败和转移等不良结果进行评估.
主要成果:
- 在RP研究中,50%表示年龄较大与更糟糕的结果有关;没有一个表明有利的影响.
- 在EBRT研究中,53%的人认为老年与更好的结果有关,21%的趋势是有利的;没有人认为有不良影响.
结论:
- 高龄 (≥70岁) 可能是男性进行激进前列腺切除术 (RP) 的不良预后因素.
- 相反,老年似乎是一个有利的预后因素,男性接受外部束辐射疗法 (EBRT).
- 需要进一步的研究来验证这些年龄治疗相互作用的发现.
相关概念视频
01:21Cancer Survival Analysis
380
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:20Disorders of the Male Reproductive System
447
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
447
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K